Growth Metrics

Angiodynamics (ANGO) Gross Profit (2016 - 2026)

Angiodynamics' Gross Profit history spans 17 years, with the latest figure at $41.5 million for Q1 2026.

  • For Q1 2026, Gross Profit rose 6.75% year-over-year to $41.5 million; the TTM value through Feb 2026 reached $170.3 million, up 10.61%, while the annual FY2025 figure was $157.7 million, 1.94% up from the prior year.
  • Gross Profit reached $41.5 million in Q1 2026 per ANGO's latest filing, down from $44.8 million in the prior quarter.
  • In the past five years, Gross Profit ranged from a high of $46.5 million in Q2 2022 to a low of $35.9 million in Q1 2024.
  • Average Gross Profit over 5 years is $41.2 million, with a median of $40.5 million recorded in 2023.
  • Peak YoY movement for Gross Profit: fell 16.92% in 2024, then increased 13.98% in 2025.
  • A 5-year view of Gross Profit shows it stood at $45.1 million in 2022, then fell by 10.68% to $40.3 million in 2023, then decreased by 0.88% to $39.9 million in 2024, then grew by 12.22% to $44.8 million in 2025, then fell by 7.38% to $41.5 million in 2026.
  • Per Business Quant, the three most recent readings for ANGO's Gross Profit are $41.5 million (Q1 2026), $44.8 million (Q4 2025), and $41.9 million (Q3 2025).